Albumin-bound paclitaxel - Abraxis BioScience

Drug Profile

Albumin-bound paclitaxel - Abraxis BioScience

Alternative Names: ABI-007; Abraxane; Coraxane; Coroxane; Nab-Paclitaxel; Systemic nanoparticle albumin-bound paclitaxel

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abraxis BioScience
  • Developer Abraxis BioScience; AstraZeneca; Australian and New Zealand Urogenital and Prostate Cancer Group; Big Ten Cancer Research Consortium; Cambridge University Hospitals; Cancer Research UK; Celgene Corporation; Columbia University; Eli Lilly; Fondazione Sandro Pitigliani; Genentech; M. D. Anderson Cancer Center; Mayo Clinic; NCIC Clinical Trials Group; New York University School of Medicine; Oncosur; PrECOG; Southeastern Gynecologic Oncology; Taiho Pharmaceutical; University of California, Davis; University of Iowa; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Small cell lung cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Bladder cancer; Ovarian cancer; Prostate cancer
  • Discontinued Coronary artery restenosis; Peripheral arterial disorders; Vascular restenosis

Most Recent Events

  • 19 Jan 2018 Updated efficacy and adverse events data from the phase II LAPACT trial in Pancreatic cancer released by Celgene Corporation
  • 19 Dec 2017 Phase-II clinical trials in Head and neck cancer (Neoadjuvant therapy, Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in USA (IV) (NCT03174275)
  • 08 Dec 2017 Adverse events data from the phase III GeparSepto trial in Breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top